Grape King Bio (TPE:1707) Piotroski F-Score: 3 (As of Jul. 08, 2026) — 40% Below Median


TPE:1707 Grape King Bio Ltd TPE:1707
78 GF Score
Price NT$91.00
GF Value NT$144.03
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Grape King Bio Piotroski F-Score?

Grape King Bio TPE:1707 -0.11% 78 Piotroski F-Score is 3 as of Jul. 08, 2026, which is 40% below its 10-year median of 5.00. GuruFocus rates TPE:1707 with a GF Score™ of 78/100 and a GF Value™ of NT$144.03 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 980 Drug Manufacturers companies, Grape King Bio ranks worse than 78.37% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Grape King Bio has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Grape King Bio's Piotroski F-Score or its related term are showing as below:

TPE:1707' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 8
Current: 3

During the past 13 years, the highest Piotroski F-Score of Grape King Bio was 8. The lowest was 3. And the median was 5.

Grape King Bio  (TPE:1707) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Grape King Bio Piotroski F-Score Related Terms


Grape King Bio Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Grape King Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grape King Bio Piotroski F-Score Chart

Grape King Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 8.00 4.00 7.00 3.00

Grape King Bio Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 4.00 6.00 4.00 3.00

TPE:1707 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grape King Bio Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Grape King Bio's Piotroski F-Score falls into.


TPE:1707
78GF Score
Grape King Bio Ltd TPE:1707
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was 207.647 + 269.737 + 296.099 + 444.822 = NT$1,218 Mil.
Cash Flow from Operations was 13.381 + 833.347 + 161.095 + 1171.989 = NT$2,180 Mil.
Revenue was 2252.295 + 2569.008 + 2427.89 + 3002.414 = NT$10,252 Mil.
Gross Profit was 1650.168 + 1963.097 + 1787.587 + 2295.958 = NT$7,697 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(15323.638 + 14939.803 + 14895.842 + 14489.483 + 15738.289) / 5 = NT$15077.411 Mil.
Total Assets at the begining of this year (Dec24) was NT$15,324 Mil.
Long-Term Debt & Capital Lease Obligation was NT$143 Mil.
Total Current Assets was NT$5,661 Mil.
Total Current Liabilities was NT$3,421 Mil.
Net Income was 257.881 + 327.759 + 415.887 + 446.772 = NT$1,448 Mil.

Revenue was 2347.519 + 2758.268 + 2899.237 + 3154.981 = NT$11,160 Mil.
Gross Profit was 1756.884 + 2164.473 + 2265.315 + 2470.883 = NT$8,658 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(15511.841 + 15596.957 + 15048.802 + 14405.899 + 15323.638) / 5 = NT$15177.4274 Mil.
Total Assets at the begining of last year (Dec23) was NT$15,512 Mil.
Long-Term Debt & Capital Lease Obligation was NT$107 Mil.
Total Current Assets was NT$5,596 Mil.
Total Current Liabilities was NT$3,323 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Grape King Bio's current Net Income (TTM) was 1,218. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Grape King Bio's current Cash Flow from Operations (TTM) was 2,180. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=1218.305/15323.638
=0.07950495

ROA (Last Year)=Net Income/Total Assets (Dec23)
=1448.299/15511.841
=0.09336732

Grape King Bio's return on assets of this year was 0.07950495. Grape King Bio's return on assets of last year was 0.09336732. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Grape King Bio's current Net Income (TTM) was 1,218. Grape King Bio's current Cash Flow from Operations (TTM) was 2,180. ==> 2,180 > 1,218 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=142.859/15077.411
=0.00947504

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=106.963/15177.4274
=0.00704751

Grape King Bio's gearing of this year was 0.00947504. Grape King Bio's gearing of last year was 0.00704751. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=5660.778/3421.232
=1.6546022

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=5596.174/3323.043
=1.68405103

Grape King Bio's current ratio of this year was 1.6546022. Grape King Bio's current ratio of last year was 1.68405103. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Grape King Bio's number of shares in issue this year was 150.023. Grape King Bio's number of shares in issue last year was 149.765. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=7696.81/10251.607
=0.75079058

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=8657.555/11160.005
=0.77576623

Grape King Bio's gross margin of this year was 0.75079058. Grape King Bio's gross margin of last year was 0.77576623. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=10251.607/15323.638
=0.66900608

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=11160.005/15511.841
=0.71945071

Grape King Bio's asset turnover of this year was 0.66900608. Grape King Bio's asset turnover of last year was 0.71945071. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Grape King Bio has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Grape King Bio (TPE:1707) has a Piotroski F-Score of 3 as of Jul. 08, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Grape King Bio and its competitors. This is 40% below median its historical median of 5.00. Over the past decade, Grape King Bio's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Grape King Bio ranks #768 out of 980 companies in the Drug Manufacturers industry, placing it in the top 78.4%.
Is Grape King Bio's Piotroski F-Score too high?
Grape King Bio's current Piotroski F-Score of 3 is 40% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Grape King Bio's value of 3 is 40% below this industry median. Based on the distribution chart, Grape King Bio ranks #768 out of 980 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Grape King Bio has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #768 out of 980 companies for Piotroski F-Score. This places Grape King Bio in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Grape King Bio's value of 3 is 40% below this benchmark. Historically, Grape King Bio's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Grape King Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current Piotroski F-Score is 3, which is 40% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Possible Value Trap. The stock's GF Value™ is NT$144.03, compared to a current price of NT$91.00 — trading 36.8% below its estimated fair value. The current Piotroski F-Score is 3, which is 40% below median its 10-year median of 5.00 and 40% below the Drug Manufacturers industry median of 5.00. Grape King Bio's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Piotroski F-Score is 3 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grape King Bio (TPE:1707) Overvalued in 2026?

Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued. The current stock price of NT$91.00 is trading 36.8% below its estimated GF Value™ of NT$144.03. GuruFocus considers Grape King Bio to be Possible Value Trap.

Key valuation signals for TPE:1707:

  • Piotroski F-Score: 3 (40% below median its 10-year median of 5.00)
  • GF Value™: NT$144.03 vs. price of NT$91.00 (36.8% below fair value)
  • GF Score™: 78/100 with 5 warning signs
  • Industry Position: 40% below the Drug Manufacturers median (#768 of 980)

No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grape King Bio Business Description

Address Jinling Road, No. 402, Section 2, Pingzhen District, Pingzhen District, Taoyuan, TWN, 324
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
78GF Score

Get the complete analysis for TPE:1707

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$91.00
Price
NT$144.03
GF Value